60755-87-5

Upstream product

• 61-54-1 tryptamine 
• 50376-97-1 methyl 3-(4,9-dihydro-3H-pyrido[3,4-b]indol-1-yl)propanoate 
• 92256-33-2 N-(2-indol-3-yl-ethyl)-succinamic acid 
• 92870-51-4 N'-<3-(methoxycarbonyl)propanoyl>tryptamine 
• 91147-07-8 3-(9H-Pyrido<3,4-b>indol-1-yl)propansaeure-methylester 
• 18122-85-5 4,5-dihydro-canthin-6-one 
• 15741-79-4 N-benzyl tryptamine 
• 65284-99-3 N_b-benzyl-1,2,3,3a,4,5-hexahydrocanthin-6-one 
• 16979-93-4 N-benzylidene-2-(1H-indol-3-yl)ethylamine 
• 26400-25-9 1,2,3,3a,4,5-hexahydrocanthin-6-one 
• 479-43-6 canthin-6-one 

Relevant academic research and scientific papers

Synthesis, in vitro antibacterial activities of a series of 3-N-substituted canthin-6-ones

An improved synthetic route of canthin-6-one was accomplished. To further enhance the antibacterial potency and improve water solubility, a series of 3-N-alkylated and 3-N-benzylated canthin-6-ones were designed and synthesized, and their in vitro antibacterial activities were evaluated. A clear structure-activity relationship with peak minimal inhibitory concentration (MIC) values of 0.98 (μg·mL-1) was investigated. Particularly, compounds 6i-r and 6t were found to be the most potent compounds with minimal inhibitory concentration (MIC) values lower than 1.95 (μg·mL-1) against Staphylococcus aureus.

Solution phase and nanoparticular biosynthetically inspired interconnections in the canthin-6-one β-carboline series and study of phenotypic properties on C. elegans

Based on the biosynthetic line of canthin-6-one alkaloids from their simple precursors such as tryptamine, the present work is focused on the study of alternative protocol of the Bischler-Napieralski reaction and has led to a full coverage of the different biosynthetic intermediates. Nanoparticles were also prepared as mimics of biosynthetic assembly lines and some interesting biological results in term of chemical ecology are also reported. Canthin-6-one, a particular representative β-carboline alkaloid, was targeted for synthesis keeping in mind its biosynthetic origin. In fact, several biosynthetic intermediates were synthesized and nanoparticular mimicry of key steps was also achieved permitting further evaluation of biological properties for this class of alkaloids. Copyright

USE OF CANTHIN-6-ONE AND ITS ANALOGS IN THE TREATMENT OF MYCOBACTERIA-LINKED PATHOLOGIES ( amended

The present invention relates to the use, for the preparation of a medicament intended for the treatment or the prevention of pathologies linked to, or caused by mycobacteria, of at least one of the compounds of the following formula (I): in which B represents in particular a nitrogen atom, and R1, R2, R3, R4, R5, R6, R7 and R8 represent in particular a hydrogen atom.

Extraction, hemisynthesis, and synthesis of canthin-6-one analogues. Evaluation of their antifungal activities

Zanthoxylum chiloperone var. angustifolium was investigated. Alkaloids 1-3 from the canthin-6-one series were characterized. Derivatives 7-28 were prepared by hemisynthesis or total synthesis. All compounds were tested for in vitro antifungal activities against five pathogenic fungal strains. Analogues of canthin-6-one did not show better antifungal activities. 2005 American Chemical Society and American Society of Pharmacognosy.